Literature DB >> 23227864

Diabetic nephropathy: causes and managements.

Yamini B Tripathi1, Durgavati Yadav.   

Abstract

Uncontrolled diabetic patients often develop diabetic nephropathy (DN). Since, it involves different molecular pathways, such as polyol pathway, protein kinase-C (PKC) activation, inflammatory and oxidative stress etc., and so multi-targeted drugs would be required for its management. Although, combination therapies with various conventional medicines are already in use, but herbal preparations are being preferred as adjuvant therapy, because of their multi targeted drug action due to the presence of natural cocktail of various secondary metabolites. This review describes pathogenesis of DN, possible approaches for its management and information about recent patents and bio-products, which are in pipe line of drug development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23227864

Source DB:  PubMed          Journal:  Recent Pat Endocr Metab Immune Drug Discov        ISSN: 1872-2148


  10 in total

1.  Association Between Cannabinoid Receptor-1 Gene Polymorphism and the Risk of Diabetic Nephropathy Among Patients with Type 2 Diabetes Mellitus.

Authors:  Xuelian Zhang; Haiqing Zhu; Xiaoyan Xing; Chunyu Zhang
Journal:  Pharmgenomics Pers Med       Date:  2020-11-12

Review 2.  Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment.

Authors:  Andrew Kowalski; Armand Krikorian; Edgar V Lerma
Journal:  Ochsner J       Date:  2014

3.  Ginseng total saponin modulates the changes of α-actinin-4 in podocytes induced by diabetic conditions.

Authors:  Tae-Sun Ha; Ji-Young Choi; Hye-Young Park; Ja-Ae Nam; Su-Bin Seong
Journal:  J Ginseng Res       Date:  2014-05-28       Impact factor: 6.060

4.  Impact of Type 2 Diabetes on Impaired Kidney Function in Sub-Saharan African Populations.

Authors:  Sally N Adebamowo; Adebowale A Adeyemo; Fasil Tekola-Ayele; Ayo P Doumatey; Amy R Bentley; Guanjie Chen; Jie Zhou; Daniel Shriner; Olufemi Adetola Fasanmade; Godfrey Okafor; Benjamin Eghan; Kofi Agyenim-Boateng; Jokotade Adeleye; Williams Balogun; Albert G Amoah; Samuel Owusu; Joseph Acheampong; Thomas Johnson; Johnnie Oli; Clement A Adebamowo; Charles N Rotimi
Journal:  Front Endocrinol (Lausanne)       Date:  2016-05-30       Impact factor: 5.555

5.  Chinese medicines in the treatment of experimental diabetic nephropathy.

Authors:  Jing-Yi Liu; Xiao-Xin Chen; Sydney Chi-Wai Tang; Stephen Cho-Wing Sze; Yi-Bin Feng; Kai-Fai Lee; Kalin Yan-Bo Zhang
Journal:  Chin Med       Date:  2016-02-24       Impact factor: 5.455

6.  Revealing Synergistic Mechanism of Multiple Components in Gandi Capsule for Diabetic Nephropathy Therapeutics by Network Pharmacology.

Authors:  Jian Zhang; Qiqiang Zhang; Xiaofei Chen; Yan Liu; Jiyang Xue; Arik Dahan; Hai Zhang; Yifeng Chai
Journal:  Evid Based Complement Alternat Med       Date:  2018-04-26       Impact factor: 2.629

7.  The Compatibility of the Treatment Modalities to the Recommendations of the Kidney Disease Outcomes Quality Initiative Guideline in Chronic Kidney Disease Patients with Diabetes.

Authors:  Zelal Adibelli; Cevdet Duran
Journal:  Iran J Public Health       Date:  2021-06       Impact factor: 1.429

Review 8.  Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease.

Authors:  Alejandra Guillermina Miranda-Díaz; Leonardo Pazarín-Villaseñor; Francisco Gerardo Yanowsky-Escatell; Jorge Andrade-Sierra
Journal:  J Diabetes Res       Date:  2016-07-20       Impact factor: 4.011

9.  Characteristics of Harmonic Indexes of the Arterial Blood Pressure Waveform in Type 2 Diabetes Mellitus.

Authors:  Chen-Kai Liao; Jaw-Shiun Tsai; Liang-Yu Lin; Si-Chen Lee; Chun-Fu Lai; Te-Wei Ho; Feipei Lai
Journal:  Front Bioeng Biotechnol       Date:  2020-07-08

10.  Clinical efficacy and safety of Chinese herbal medicine for the treatment of patients with early diabetic nephropathy: A protocol for systematic review and meta-analysis.

Authors:  Xiaomei Yang; Chenling Hu; Shengju Wang; Qiu Chen
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.